Article Text

Download PDFPDF
The continuum of screening and early detection, awareness and faster diagnosis of lung cancer
  1. Michael D Peake1,2,3,4,
  2. Neal Navani5,6,
  3. David R Baldwin7
  1. 1 Department of Respiratory Medicine, University of Leicester, Leicester, UK
  2. 2 Centre for Cancer Outcomes, Cancer Collaborative, University College London Hospitals, London, UK
  3. 3 National Cancer Registration and Analysis Service, Public Health England, London, UK
  4. 4 Department of Thoracic Medicine, University College London Hospitals, London, UK
  5. 5 Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK
  6. 6 Department of Early Diagnosis and Health Professional Engagement, Cancer Research UK, London, UK
  7. 7 Department of Respiratory Medicine, University of Nottingham, Nottingham, UK
  1. Correspondence to Dr Michael D Peake, Respiratory Medicine, University of Leicester, Leicester LE1 7HA, UK; mick.peake{at}

Statistics from

The principal reason lung cancer outcomes are poor is that most patients are diagnosed with what, with current technologies, is incurable disease. Despite unprecedented recent advances in the understanding of the biology, oncogenesis and immunology of cancer, and the subsequent development of innovative systemic therapies for lung cancer, the long-term prognosis for patients beyond stages I and II remains poor. The cost of the new agents, largely indicated for people with advanced disease and good performance status (PS), is such that the International Agency for Research on Cancer recently said that ‘No country can afford to treat its way out of the cancer problem’.1 In any case, many patients with advanced disease are ineligible because of poor performance status.

Although lung cancer survival rates have been improving in England since 2006,2 the latest data from the Concord study still rate the UK behind many other nations.3 Later diagnosis is likely a major factor explaining the consistent observation that the proportion of patients that have early stage disease at the time of diagnosis in the UK is less than in many comparator countries.4 In a recent study comparing older patients with non-small cell lung cancer (NSCLC) in England with those in the USA, 15% were diagnosed at stage I in England compared with 25% in the USA.5

To address these issues, we need to consider ways in which we can detect lung cancer at an earlier stage to increase the curative treatment rate, and where cancer is detected at a later stage, provide rapid work-up to minimise deterioration in fitness to maximise the impact of systemic therapy. Essentially this means: screening of people at relatively high risk of lung cancer; using public and professional awareness campaigns to promote the earlier referral of patients with symptoms suspicious …

View Full Text


  • Contributors MP was commissioned to write this editorial and wrote the first draft. DB and NN made significant comments and amendments and the final version was agreed by all authors.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Lung cancer
    Martyn P T Kennedy Leanne Cheyne Michael Darby Paul Plant Richard Milton Jonathan M Robson Alison Gill Puneet Malhotra Victoria Ashford-Turner Kirsty Rodger Elankumaran Paramasivam Annette Johnstone Bobby Bhartia Shishir Karthik Catherine Foster Veronica Lovatt Francesca Hewitt Louise Cresswell Victoria H Coupland Margreet Lüchtenborg Ruth H Jack Henrik Moller Matthew E J Callister